Implications of placebo and nocebo effects for clinical practice:

Expert consensus

Andrea W.M. Evers¹, Luana Colloca⁶, Charlotte Blease⁵, Marco Annoni⁷, Lauren Y. Atlas⁸, Fabrizio Benedetti⁹, Ulrike Bingel⁸, Christian Büchel¹⁰, Claudia Carvalho¹¹, Ben Colagiuri¹², Alia J. Crum¹³, Paul Enck¹, Jens Gaab¹⁴, Andrew L. Geers¹⁵, Jeremy Howick¹⁶, Karin B. Jensen¹⁷, Irving Kirsch¹⁸, Karin Meissner¹⁹, Vitaly Napadow¹⁰, Kaya J. Peerdeman¹⁰, Amir Raz¹, Winfried Rief¹⁰, Lene Vase¹¹, Tor D. Wager¹², Bruce E. Wampold¹³, Katja Weimer¹⁴, Katja Wiech¹⁸, Ted J. Kaptchuk¹⁹, Regine Klinger²⁰, John M. Kelley²¹

as consort of placebo experts

Correspondence address:
Andrea W.M. Evers, Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, PO Box 9555, 2300 RB Leiden, the Netherlands, a.evers@fsw.leidenuniv.nl
Implications of placebo and nocebo effects

Health, Medical and Neuropsychology unit, Institute of Psychology, Leiden University, the Netherlands

Departments of Pain Translational Symptoms Science and Anaesthesiology, School of Nursing and Medicine, University of Maryland Baltimore, Baltimore, US

General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts, US

Institute of Biomedical Technologies, National Research Council, Rome, Italy

Section on Affective Neuroscience and Pain, NIH, Bethesda, Maryland, US

Physiology and Neuroscience, University of Turin Medical School, Turin, Italy

Department of Neurology, University Hospital Essen, Essen, Germany

Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Department of Clinical and Health Psychology, Instituto Universitário de Ciências Psicológicas, Lisbon, Portugal

School of Psychology, University of Sydney, Sydney, Australia

Department of Psychology, Stanford University, Stanford, California, US

Department of Psychosomatic Medicine and Psychotherapy, University Hospital Tubingen, Tubingen, Germany

Faculty of Psychology, University of Basel, Basel, Switzerland

Department of Psychology, University of Toledo, Toledo, Ohio, US

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

Beth Israel Deaconess Medical Center, Program in Placebo Studies, Massachusetts, US

Institut für Medizinische Psychologie, Ludwig-Maximilians-Universität München, München, Division of Health Promotion, University of Applied Sciences, Coburg, Germany

Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, US

Departments of Psychiatry, Neurology & Neurosurgery, McGill University, Montreal, Canada

Department of Clinical Psychology and Psychotherapy, Philipps University of Marburg, Marburg, Germany

Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark

Department of Psychology and Neuroscience, University of Colorado, Boulder, Colorado, US

Department of Counseling Psychology, University of Wisconsin-Madison, Madison, Wisconsin, US and Modum Bad Psychiatric Center, Norway.

Clinic for Psychosomatic Medicine and Psychotherapy, University Hospital Ulm, Ulm, Germany.

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Implications of placebo and nocebo effects

Abstract

**Background:** Placebo and nocebo effects occur in clinical or laboratory medical contexts after administration of an inert treatment or as part of active treatments and are due to psychobiological mechanisms such as expectancies of the patient. Placebo and nocebo studies have evolved from predominantly methodological research into a far-reaching interdisciplinary field that is unravelling the neurobiological, behavioural and clinical underpinnings of these phenomena in a broad variety of medical conditions. As a consequence, there is an increasing demand from health professionals to develop expert recommendations about evidence-based and ethical use of placebo and nocebo effects for clinical practice.

**Methods:** A survey and interdisciplinary expert meeting by invitation was organized as part of the 1st Society for Interdisciplinary Placebo Studies (SIPS) conference in 2017. Twenty-nine internationally recognized placebo researchers participated.

**Results:** There was consensus that maximizing placebo effects and minimizing nocebo effects should lead to better treatment outcomes with fewer side effects. Experts particularly agreed on the importance of informing patients about placebo and nocebo effects, and training health professionals in patient-clinician communication to maximize placebo and minimize nocebo effects.

**Conclusions:** The current paper forms a first step towards developing evidence-based and ethical recommendations about the implications of placebo and nocebo research for medical practice, based on the current state of evidence and the consensus of experts. Future research might focus on how to implement these recommendations, including how to optimize conditions for educating patients about placebo and nocebo effects, and providing training for the implementation in clinical practice.
Implications of placebo and nocebo effects

Introduction

Placebo and nocebo research has now evolved from a methodological consideration within clinical research to a distinct and expanding interdisciplinary field in its own right. Placebo studies encompass a broad variety of disciplines from biomedicine and neuroscience, to the social and behavioural sciences, and the humanities (1-14). Placebo and nocebo effects refer to the beneficial or adverse effects that occur in clinical or laboratory medical contexts, respectively, after administration of an inert treatment or as part of active treatments, due to mechanisms such as expectancies of the patient. Current research incorporates both the study of placebo and nocebo responses as an outcome in clinical trials as well as the study of placebo and nocebo effects and their psychological and neurobiological mechanisms in various clinical applications, including many medical disciplines. Current objectives in the field are to produce cross-disciplinary conceptualizations of placebo and nocebo effects; to re-evaluate the ethics of placebos in clinical trials and practice; and to initiate the ethical translation of empirical findings into clinical practice.

Robust empirical evidence now demonstrates that placebo and nocebo effects are both significant and measurable for many conditions (e.g., pain, depression, Parkinson’s disease, fatigue, allergies, and immune deficiencies) (1). Importantly, placebo and nocebo effects can substantially modulate the efficacy and tolerability of active pharmacological or other medical treatments (15,16). This empirical evidence from experimental and clinical studies challenges health care professionals to translate and implement the findings of placebo and nocebo research into practice. This translation relates not only to the possible use of placebos as part of regular treatments (e.g. placebo pills), but far more importantly, to the systematic utilization of the mechanisms underlying placebo and nocebo effects to augment established treatment strategies (e.g. attention to expectations and empathy in patient-clinician communication).

Due to the interdisciplinary nature of this emerging field with its potentially wide applications across health care, there is a need to develop and formalize guidelines on the available evidence, including
the possible implications of placebo and nocebo effects for clinical practice (17). While the American Medical Association (AMA) provides explicit guidelines on the clinical use of placebos, the General Medical Council (GMC) in the UK provides no such ethical guidelines (18). Notwithstanding the content of ethical guidelines and codes, studies reveal that the use of both pure (e.g. sugar pill) and impure (e.g. antibiotics for viral infections) placebos by doctors is widespread (19-21): for example, in the US, 55% of internists and rheumatologists report using placebos; in the UK, 77% of primary care doctors reported that they use placebos at least once per week, while 86% of primary care doctors in Denmark admitted that they used placebos at least once within the last year. Surveys aimed at investigating patients’ attitudes reveal that the majority of respondents believe that placebo use by doctors is acceptable under certain circumstances (22). Until now, however, there has been no study of expert opinions in placebo and nocebo studies about the implications of this research for clinical practice.

To address this gap, a clinical expert meeting was organized to survey established placebo researchers’ views about placebo and nocebo effects and their translation into clinical practice. The aim of this survey and meeting was to develop a consensus on clinical recommendations based on the current state of the art in placebo and nocebo research among experts in the field.

**Methods**

**Expert group:** Of the 31 invited speakers at the 1st official Society for Interdisciplinary Placebo Studies (SIPS) conference, 29 agreed to take part; the two who chose not to participate indicated that their research was not clinically focused. The 29 invited experts completed the survey, of whom four invited speakers were unavailable to participate due to personal circumstances. A workgroup of six members (AE, LC, CB, RK, TK, JK) prepared the survey and expert meeting.

The 29 participants were from 12 different countries, had an average age of 49.1 (SD 11.1), and 45% were female. In total, 65.5% worked clinically (17.2% physicians, 41.4% psychologists, and 6.9%
Implications of placebo and nocebo effects

acupuncturists). The participants’ backgrounds included anaesthesiology, neurology, cognitive neuroscience, primary care, internal medicine, psychiatry, psychosomatic medicine, health and medical psychology, clinical psychology, epidemiology, medical ethics, and philosophy. The participants had on average 14.2 years (SD 8.0) of research experience in the field of placebo and nocebo studies or related areas since their doctoral degree.

Survey: Based on a literature review of the relevant empirical evidence on possible clinical applications of placebo and nocebo effects, a survey was developed that focused on four themes: A) Prescription of placebo as regular treatment, B) Open label prescription of placebo, C) Nocebo effects, and D) Patient-clinician communication. Subsequently, items for each theme were developed and checked by all members of the workgroup for relevance, readability, and clarity. This process yielded 40 items in all, 10 for each theme. Participants were asked to read each statement and rank it on a 0-10 scale with zero meaning “totally disagree” and ten meaning “totally agree.” In addition, participants had the opportunity to provide written comments on each item (see Supplementary Appendix Table S1 for a complete overview of the survey). The survey was analysed by calculating the mean score for each item. High agreement for a statement was defined as a mean score ≥ 8, and high agreement against a statement was defined as a mean score ≤ 2 on the 10-point scale. Items that resulted in more mixed levels of agreement (scores between 2 and 8) were not discussed at the clinical expert meeting.

Clinical expert meeting: The clinical experts met in a 1-day pre-conference session in Leiden, the Netherlands, on April 2, 2017. At this meeting, the results of the survey and possible recommendations and discussion points were explored in plenary sessions. Consensus was reached based upon results of the survey and the discussion during the meeting. The meeting was audio-recorded and minutes were taken.
Implications of placebo and nocebo effects

Results

In the sections below, we describe the main results of the survey and expert meeting. The initial discussion centred on defining important components of the placebo concept. We then summarize the survey statements with high agreement, as well as the related evidence, together with relevant comments discussed at the clinical expert meeting. A summary of the recommendations is listed in Table 1.

Conceptualization of placebo effect and placebo response

The experts agreed that it is crucial to distinguish between placebo and nocebo responses versus placebo and nocebo effects. *In line with the drug terminology proposed by Fisher (1965) (23), the placebo and nocebo response include all health changes that result after administration of an inactive treatment (i.e., differences in symptoms pre and post treatment), thus including natural history and regression to the mean. The placebo and nocebo effect refer to the changes specifically attributable to placebo and nocebo mechanisms, including the neurobiological and psychological mechanisms of expectancies. These mechanisms are shaped, for example, by verbal instruction, or nonverbal or situational cues that affect treatment expectancies (see also communication SIPS community, 29 July 2016) (24).* Importantly, placebos and nocebos not only have effects during the prescription of placebo pills, but they can also substantially modulate the efficacy and tolerability of active pharmacological or other medical treatments. There was strong consensus that recommendations should be based on the research evidence on placebo and nocebo effects, including the involved mechanisms (e.g. expectancies), and their consequences for medical practice (e.g. patient-clinician communication).
Implications of placebo and nocebo effects

Results of the survey and expert meeting

Considering placebo effects as part of regular treatment

There was a consensus regarding the importance of making optimal use of placebo effects to achieve better treatment outcomes (A1) and of optimally informing patients about placebo effects (A8), for example, to explain that a patient might improve due to factors other than the treatment itself, such as expectancies regarding treatment prognosis. The consensus was based primarily on the broad evidence that now exists for placebo and nocebo effects on clinical, neurobiological, and laboratory outcomes, at least for the areas of pain, depression, Parkinson’s disease, fatigue, allergies, and immune deficiency (1-14). However, the experts also acknowledged the current lack of knowledge about how best to provide this information to patients to ensure that patients are optimally informed. For example, there is insufficient knowledge about the ways in which patients and health care providers can maximize placebo effects and minimize nocebo effects over time during repeated interactions and treatments (25).

The experts strongly agreed that clinicians should not prescribe or practice more invasive treatments simply to engender more potent placebo effects (A7). Although some systematic reviews have found that more intensive and invasive treatments can augment placebo effects, results are not consistent and are often moderated by factors such as the symptom or condition treated or the specific procedures used (26). Moreover, there are clear practical and ethical restrictions on prescribing more invasive treatments for the sake of producing stronger placebo effects, since these procedures are often more expensive and entail a higher risk of undesirable side effects. Consequently, the experts agreed that prescription of more intensive and invasive treatment (e.g. injections instead of pills) to increase placebo effects is not justified.
Implications of placebo and nocebo effects

Open label placebo

Where open label placebo (i.e., prescription of placebo pills with the knowledge and assent of the patient) was concerned there was relatively high consensus that these should be preferred to hidden placebos (B3). Importantly, there are compelling ethical arguments for informing patients about placebo treatments in clinical contexts (27). Related to these findings, the majority of the experts strongly agreed that deception is not necessary for placebo effects to occur (B2). This viewpoint is empirically supported by recent studies in patients with irritable bowel syndrome and chronic pain, which showed beneficial effects of open label placebo on primary symptom outcomes, such as pain or disability (28-31). However, more research is needed in other conditions and patient groups before recommendations can be developed about their possible use in clinical practice. For example, non-significant findings were found in a pilot study in patients with a major depressive disorder in a small sample of 12 patients, although the medium effect size was comparable to the other trials (32,33). It has also to be established whether specific patient groups or subgroups of patients benefit more than others from open label placebos, or whether biological or psychological markers are associated with the effectiveness of these open label placebo strategies. Promising is the case of dose-extending placebos (e.g., placebo given along with active medication) that mimic the psychobiological responses that are associated with the effectiveness of the medications with the potential of reducing side effects and costs (32). Although prescription of placebos is not yet regulated in any part of the world and additional research is necessary on its short- and long-term effects, open label prescription of placebos could be considered as a possible future watch and wait strategy or for use in long-term conditions when other treatment options have failed (33).

Nocebo effects

There was a consensus regarding strategies to minimize and prevent nocebo effects. Experts agreed that nocebo effects should be explained to patients (C1), and that information about side effects
Implications of placebo and nocebo effects

should be presented in such a way that nocebo effects are minimized (C4). The relatively strong consensus regarding optimally informing patients to minimize nocebo effects might be due to its high clinical relevance, which is based on findings that nocebo effects have been shown to consistently worsen treatment outcomes and to be at least in part responsible for side effects (6,10-12,353). Indeed, there is convincing evidence that the way in which patients are informed about risks and side effects influences the likelihood of their occurrence. For example, when reassuring words are used during a local anaesthetic injection instead of emphasizing the pain experience during the procedure, pain reports can be reduced (364). However, there are several ethical considerations that are required for optimal informed consent of patients, including balancing the need for honesty and transparency with the requirement that harms should not be induced or increased unnecessarily. For example, tailored strategies might be applied after the necessary information has been offered, depending on the patient’s need for more detailed information on the risks and side effects of treatment. Such strategies might be particularly useful for those patients who have a high risk of developing nocebo effects, such as individuals who exhibit high levels of somatic amplification or fear of side effects (7,10,11,353). Moreover, evidence is needed about the consequences of systematically informing patients about the role of nocebo effects, for example, by introducing the terminology of nocebo effects, or determining the optimal moment for informing patients about nocebo effects during ongoing treatments (375).

There was also consensus that clinicians should receive training and education to minimize nocebo effects (C8 and C9). Training and education might include informing health professionals about the negative impact of nocebo effects, as well as training them in strategies for optimal verbal and non-verbal communication, including information about risks and side effects (7,9-11,353-375). Again, however, there was acknowledgement that there has been a lack of research into the education and training of health professionals in relation to nocebo effects. Future studies might focus on evaluating different types of educational strategies to obtain insight into the most effective tools for
Implications of placebo and nocebo effects

training professionals to minimize nocebo effects (e.g., how information is communicated) as well as into optimal modes of education and training (e.g., including virtual reality tools).

**Patient-clinician communication**

The results of the survey showed a high level of agreement regarding patient-clinician communication (4 of 10 survey items). Experts agreed that a good patient-clinician relationship is essential to make optimal use of placebo effects to increase therapeutic efficacy (D2). Indeed, evidence is mounting that characteristics such as trust, warmth, and empathy are helpful in medical communication to foster placebo effects (386,397). In addition, there was clear consensus that clinicians should receive regular education and training about how to make optimal use of placebo effects in their treatments (D6 and D7). However, studies examining which elements this training might include are scarce (17). For example, a critical point in the patient-clinician communication is how to optimize expectancies without risking subsequent violation of patient’s expectations and how to avoid eliciting overly positive expectations that might harm trust in the treatment. An important step will be to study specific features of disclosures (e.g. content, setting) with the aim of ethically tailoring education and training towards maximizing placebo and minimizing nocebo effects. Finally, experts agreed that medical ethics education encompassing placebo and nocebo effects should be a routine part of clinician training (D8).

**Discussion**

Intensive research in recent decades provides substantial evidence for the potential benefits of placebo effects, as well as the possible harms of nocebo effects (1-14). In this survey of international experts on placebo research, there was strong consensus that patients should be informed about placebo and nocebo effects, and that healthcare professionals should be trained to maximize
Implications of placebo and nocebo effects

placebo effects and minimize nocebo effects. The current paper forms a first step towards developing evidence-based and ethical recommendations about the implications of placebo and nocebo research for medical practice, based on the current state of evidence and the consensus of experts.

More research is needed in areas such as the prescription of open label placebos, the optimization personalization of intervention strategies to maximize placebo effects and minimize nocebo effects, and generalizability across different conditions. For example, it is important to ascertain which specific strategies for informing and educating patients and health professionals work best, as well as the optimal timing for the delivery of these interventions. It is also relevant to study the possible additive or interactive effects of different ways to maximize placebo effects, such as optimally informing patients, changing environmental cues, or using conditioning during medical procedures. This might be particularly urgent in the area of nocebo effects, for example for those patients who have a higher risk of developing severe adverse events due to high levels of fear of side effects or previous traumatic medical procedures. Large-scale research should also be encouraged with the aim to understand the substantial individual differences between placebo and nocebo responders and the possible neurobiological, psychological, and genetic predictors. In addition, both condition- and treatment-related predictors have to be taken into account (e.g. disease severity, length of the treatment) (1-14)

Finally, previous evidence for the context dependency of placebo effects emphasizes the need for further research into the interaction of stable predictors with situational factors (40).

This paper focuses on the possible clinical implications of placebo and nocebo effects. However, both placebo and nocebo effects as well as responses are key themes for further study in health research. For example, the probability of placebo assignments frequently contributes to the placebo response in clinical trials, showing larger effects in trials with a higher chance of getting the real treatment in comparison to the placebo conditions (2,3,41,42). The addition of a hidden or unpredictable
Implications of placebo and nocebo effects

**Prescription of the treatment might be a future path to minimize these placebo responses in clinical trials** (2,3). However, the development of clinical implications largely depends upon research on placebo and nocebo effects, based on the understanding of their underlying mechanisms and the development of innovative interventions. Importantly, these clinical implications involve placebo and nocebo effects upon administration of an inert substance or as an active treatment, since both are affected by comparable mechanisms such as the patient’s expectancies (1-5). It is also important to emphasize that these recommendations cannot be generalized in a straightforward manner to non-medical contexts, such as psychotherapy (4344). Several relevant areas, such as the promising field of pharmacological conditioning, or predictors of placebo and nocebo effects, were omitted from the survey because so far the relevant evidence is only preliminary (1-14, 3944-4641). Finally, we did not focus on specific determinants of placebo and nocebo effects such as cultural, ethnic, neurobiological, or personal characteristics of patients, and the specific ethical and philosophical concerns that these factors raise.

Placebo and nocebo studies constitute a scientifically mature field of interdisciplinary research with applications in different medical disciplines and conditions. This burgeoning research calls for evidence-based recommendations for health professionals in medical practice. The initiative of the current survey and expert meeting is an important step towards the development of future guidelines aimed at helping medical clinicians and other health professionals to improve health care in their daily practice.
Implications of placebo and nocebo effects

Reference list


Implications of placebo and nocebo effects


25. Annoni M, Franklin G. Placebo effects and the ethics of therapeutic communication: a pragmatic
Implications of placebo and nocebo effects


36. Varelmann D, Pancaro C, Cappiello EC, Camann WR. Nocebo-induced hyperalgesia during
Implications of placebo and nocebo effects


Implications of placebo and nocebo effects

Acknowledgment

We would like to acknowledge the following colleagues for their support in the preparation of the survey and meeting described in this paper: G Einthoven, J Tekampe, DS Veldhuijzen, JWR van Leusden, JAB Mink, and AE Breugem.

Funding sources

This report was supported by an ERC Consolidator Grant, granted to AWM Evers (ERC-2013-CoG 617700 EXPECT HEAL-TH); grants of the National Institutes Health, granted to L Colloca (NIDCR, R01DE025946) and granted to V Napadow (NCCIH, R61-AT009306; Office of Director, OT2-OD023867); as well as an Irish Research Council/Marie Skłodowska Curie Global Fellowship, granted to C Blease (CLNE/2017/226). The funders had no role in the acquisition or analysis of the data or the content of this article.

Disclosure Statement

The authors have no conflict of interest to disclose.
Implications of placebo and nocebo effects

**Table 1. Summary of the recommendations formulated by the expert group**

**Do**

1. Consider placebo effects as part of regular treatment.

2. Inform patients about placebo and nocebo effects in such a way that treatment effects are maximized and side effects are minimized.

3. Ensure a patient-clinician relationship that is characterized by trust, warmth, and empathy, in order to maximize placebo effects and minimize nocebo effects.

4. Train healthcare providers in patient-clinician communication to maximize placebo effects and minimize nocebo effects.

5. Prefer open label rather than hidden placebo prescription in those cases where there is evidence for efficacy and where prescribing a placebo is legal.

**Don’ts**

1. Do not take risks (e.g., prescribing invasive treatments) to maximize placebo effects.

2. Do not consider deception a necessary component of placebo effects.